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Overexpression of interleukin 6 (IL-6) has been proposed to contribute to pulmonary 
fibrosis and other fibrotic diseases. However, the regulatory mechanisms and the role 
of IL-6 in fibrosis remain poorly understood. Epigenetics refers to alterations of gene 
expression without changes in the DNA sequence. Alternation of chromatin accessibility 
by histone acetylation acts as a critical epigenetic mechanism to regulate various gene 
transcriptions. The goal of this study was to determine the impact of IL-6 in paraquat 
(PQ)-induced pulmonary fibrosis and to explore whether the epigenetic regulations may 
play a role in transcriptional regulation of IL-6. In PQ-treated lungs and macrophages, we 
found that the mRNA and protein expression of IL-6 was robustly increased in a time- 
dependent and a dose-dependent manner. Our data demonstrated that PQ-induced IL-6 
expression in macrophages plays a central role in pulmonary fibrosis through enhanced 
epithelial-to-mesenchymal transition (EMT). IL-6 expression and its role to enhance 
PQ-induced pulmonary fibrosis were increased by histone deacetylase (HDAC) inhibition 
and prevented by histone acetyltransferase (HAT) inhibition. In addition, the ability of 
CRISPR-ON transcription activation system (CRISPR-ON) to promote transcription of 
IL-6 was enhanced by HDAC inhibitor and blocked by HAT inhibitor. Chromatin immu-
noprecipitation experiments revealed that HDAC inhibitor increased histones activation 
marks H3K4me3 and H3K9ac at IL-6 promoter regions. In conclusion, IL-6 functioning 
through EMT in PQ-induced pulmonary fibrosis was regulated dynamically by HDAC and 
HAT both in vitro and in vivo via epigenetically regulating chromatin accessibility.
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inTrODUcTiOn
Pulmonary fibrosis is a chronic, progressive inflammatory disease of pulmonary interstitial, the 
occurrence of which is about 1/10,000 and the survival rate is 30–50% at 5 years after diagnosis (1–3). 
The main pathological change associated with this disease is lung interstitial, which is characterized 
by cell proliferation and extracellular matrix (ECM) excessive accumulation (2, 4). The mechanisms 
involved remain undefined; however, growing evidences indicate that inflammatory, epithelial 
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injury, and apoptosis, especially epithelial-to-mesenchymal tran-
sition (EMT) may play an important role in the development of 
pulmonary fibrosis (5–8). EMT is a process that loss of epithelial 
cells characteristics (e.g., intercellular junctions and apical–baso-
lateral polarity) but gain mesenchymal functions (e.g., produce 
ECM components, migration, and invasion). During the EMT 
process, the mesenchymal markers such as α-smooth muscle 
actin (α-SMA) and vimentin are overexpressed, while epithelial 
markers such as E-cadherin and cytokeratin are low expressed 
(7, 9–11). Paraquat (PQ, 1, 1′-dimethyl-4, 4′-bipyridinium) 
is a highly toxic herbicide, which is widely used in numerous 
developing countries around the world. Ingestion of PQ leads to 
multiple organ damage especially in the lung, including epithelial 
cell destruction, pulmonary edema, and inflammation, which 
are considered to be mediated by the overproduction of reactive 
oxygen species. PQ induced progressive pulmonary fibrosis, the 
most serious lung damage is often associated with high mortality, 
appears as early as several days to several weeks after PQ inges-
tion (12). However, the underlying molecular mechanisms of 
which remain elusive.
Interleukin 6 (IL-6), as a multifunctional cytokine, is involved 
in the pathogenesis of various autoimmune and chronic inflam-
matory diseases through different signaling pathways (13). It is 
produced by various cells, but the main sources are macrophages 
and monocytes (14, 15). Macrophage, a key component of 
immune responses, is a predominant regulator of inflammation 
in diseases. IL-6 that is released from macrophages into the 
extracellular space can also influence fibrosis and inflammation 
via paracrine actions on other cell types. IL-6 exerts its biological 
activities through IL-6R and gp130. When IL-6 binds to mIL-6R 
(membrane-bound form of IL-6R), homodimerization of gp130 
is induced and form a high-affinity functional receptor complex 
of IL-6, IL-6R and gp130. The homodimerization of receptor 
complex activates Janus kinases (JAKs) that then phosphoryl-
ate tyrosine residues in the cytoplasmic domain of gp130. The 
gp130-mediated JAK activation by IL-6 triggers two main signal-
ing pathways: the gp130 Tyr759-derived SHP-2/ERK MAPK 
pathway and the gap130 YXXQ-mediated JAK/STAT pathway 
(16). IL-6 can simultaneously generate functionally distinct or 
sometimes contradictory signals through its receptor complex, 
IL-6Ralpha and gp130. The final physiological output is thought 
to be a consequence of the diverse signaling pathways generated 
by a given ligand (17). IL-6 induction promotes collagen depo-
sition in multiorgans such as kidney, heart, and skin (18). The 
cytokine IL-6 is elevated in mice and humans with pulmonary 
fibrosis (17, 19–23). However, its impact on fibrosis and regula-
tory mechanisms are not well understood.
Epigenetics refer to alterations of gene expression without 
changes in the DNA sequence. It is an area of research that 
encompasses three main mechanisms: DNA methylation, his-
tone modifications to the tails of histones, and also non-coding 
RNAs including long and short non-coding RNAs (24). These 
three mechanisms all seek to regulate gene expression. The new 
emphasis on epigenetics is related to the increasing production 
of drugs capable of interfering with epigenetic mechanisms and 
able to trigger better clinical responses. The role of epigenetics in 
pulmonary fibrosis is a very novel area of investigation and while 
epigenetic modifiers have been shown to influence pulmonary 
fibrosis and chronic obstructive pulmonary disease (COPD) in 
experimental models and human diseases (25–29).
Histone modification, as an epigenetic mechanism, includ-
ing acetylation, methylation, phosphorylation, deamination, 
β-N-acetylglucosamine, ADP ribosylation, ubiquitination, and 
sumoylation of Histones, can change the charge of histones which 
subsequently affect the structure of chromatin to upregulate or 
downregulate gene expression. For example, histone acetylation, 
the most common alteration of histone, is catalyzed by histone 
acetyltransferases (HATs) and histone deacetylases (HDACs). 
While HATs transfer an acetyl group from acetyl CoA to the 
ε-amino group of lysine side chains, HDACs remove an acetyl 
group from the lysine tail (30). The acetylated state of histone 
neutralizes its positive charge which may weaken the interac-
tion between histone and the DNA strands. Thereby acetylation 
results in the N-terminus of histones, due to its negatively charged 
phosphate backbone, to move away from the DNA strands (31). 
These changes lead to a more open chromatin structure thus 
upregulating gene expression. In general, increased acetylation of 
histone residues is thought to weaken the interaction with DNA 
and thus provide greater accessibility to regulatory elements of 
DNA, while deacetylation of histone provides transcriptional 
repression to regulatory elements of DNA. The HDAC enzymes 
are a multi-class with 18 members that are referred to as class 
I (HDACs1–3 and 8), class II (HDACs 4–7, 9–10), class III 
(SIRT1–7), and Class IV (HDAC11) on the basis of function and 
sequence homology (32). The inhibitions of HDACs, in theory, 
decrease histone deacetylation, provide greater accessibility to 
chromatin structure, and increase gene expression, while the 
inhibitions of HATs reduce gene expression. In contrast, the abil-
ity of HDAC inhibitors to modify gene expression is complex, 
previous studies demonstrated that approximately 30% of the 
transcriptome are regulated by HDACs with equal proportion 
of the upregulation and downregulation in gene expression, 
and the pattern and direction of changes in gene expression are 
different and depended on cell types (33, 34). This is partially 
due to the fact that HDAC inhibitors can significantly increase 
the deacetylation of histones at multiple genomic DNA regions 
(33). The mechanisms influencing IL-6 expression in pulmonary 
fibrosis are not yet known, and epigenetic control of IL-6 expres-
sion is, in general, poorly understood.
As a RNA-guided transcriptional activator system, CRISPR- 
ON is a novel and powerful tool that can effectively induce spe-
cific gene expression (35, 36). The CRISPR-ON consists of three 
components: a nucleolytically inactive Cas9–VP64 fusion, a sin-
gle guide RNA (sgRNA) incorporating two MS2 RNA aptamers at 
the tetraloop and stem-loop, and the MS2-P65-HSF1 activation 
helper protein. With the ability to robustly activate coding and 
non-coding elements (lincRNA), CRISPR-ON could be used to 
regulate gene expression epigenetically (37).
Therefore, the aim of this study was to determine the impact 
of IL-6 in PQ-induced pulmonary fibrosis and to explore whether 
the epigenetic regulators play a role in the transcriptional regula-
tion of IL-6.
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MaTerials anD MeThODs
animals
This study was carried out in accordance with the guidelines of 
Institute for Laboratory Animal Research of the Nanjing Medical 
University. The protocol was approved by the Animal Care and 
Ethical Committee of Nanjing Medical University. Male mice 
(C57BL/6 mice, Oriental Bio Service Inc., Nanjing), weighing 
20–25 g (7–8 weeks) at beginning of experiment, were used. The 
animals were maintained in a constant environmental condi-
tion (temperature 23 ±  2°C, humidity 55 ±  5%, 12:12  h light/
dark cycle) in the Animal Research Center of Nanjing Medical 
University. They had free access to food and water before and 
after all procedures.
Treatment of Mice
Mice were treated with intraperitoneal (i.p.) injections of PQ 
(Sigma, St. Louis, MO, USA) 10 or 50 mg/kg, respectively (38, 
39). Control mice were injected with the same volume of vehicle. 
Mice were harvested on day 3, and samples were used to study 
PQ-induced pulmonary acute inflammation.
Mice were treated with i.p. injections of low dose of PQ 10 mg/
kg for 1 month. Control mice were injected with the same volume 
of vehicle. Mice were sacrificed and samples were collected at the 
end of this study to determine the effect of PQ on pulmonary 
fibrosis.
In vivo neutralization of IL-6 trans-signaling was performed 
using recombinant gp130Fc chimera (R&D Systems, Minneapolis, 
MN, USA). Mice were injected with saline or PQ 10  mg/kg, 
respectively, for 33 days. Mice were treated with vehicle (200 µl 
sterile PBS) or gp130Fc (2 µg/mouse reconstituted in 200 µl sterile 
PBS) 1 h before and 18 days after PQ injection (18, 40), and then 
mice were sacrificed and samples were collected to assess changes 
in pulmonary phenotype.
To study HDAC and HAT inhibition effect on pulmonary 
acute inflammation, mice were treated with i.p. injections of PQ at 
10 mg/kg for 3 days. Anacardic acid (Selleck Chemicals, Houston, 
TX, USA) is a potent inhibitor of HAT, and VPA is an antagonist 
of HDAC. Valproic acid sodium salt (VPA, Selleck Chemicals, 
Houston, TX, USA) (3.5 mg/kg) (41) or anacardic acid (5 mg/kg) 
(42, 43) was injected 24 h and 1 h before PQ injection. Control 
mice were injected with the same volume of vehicle. To study 
HAT inhibition effect on pulmonary fibrosis, mice were treated 
with i.p. injections of PQ at 10 mg/kg for 1 month. Anacardic 
acid (5 mg/kg) was given 1 h before PQ injection and 24 h and 
15 days after PQ injection. Control mice were injected with the 
same volume of vehicle. Samples were collected on day 30 after 
PQ injection.
isolation of Bone Marrow-Derived 
Macrophages
The femurs of male C57BL/6 mice (7–8  weeks old) were iso-
lated and removed after euthanasia. Bone marrow cavities were 
flushed with PBS with 5% penicillin–streptomycin. Flushed 
cells were pelleted and resuspended in RPMI 1640 media 
(Hyclone, South Logan, UT, USA) supplemented with 10% 
FBS and 30% L929 media supplement. Then, flushed cells were 
plated in six-well plates at a density of 1.5–2 × 106 cells/well and 
incubated at 37°C, 5% CO2. On day 7, macrophages were treated 
for experiment.
To make L929 media supplement, L929 cells were plated at a 
density of 4 × 106 cells/100-mm cell culture dishes in 10 ml media 
consisting of RPMI 1640 with 1% penicillin–streptomycin, 1% 
l-glutamine, and 10% FBS.
cell culture and Treatment
To study the effect of PQ on macrophages, cells were incubated 
with vehicle or increasing concentration of PQ 20, 40, 60, and 
80 µM for 24 h. For time course experiment, cells were treated 
with PQ 80  µM, and samples collected on 4, 8, 12, and 24  h. 
For HDAC and HAT inhibition experiment, macrophages were 
treated with VPA (1 mM) (44) or anacardic acid (25 µM) (45) 1 h 
ahead of PQ 80 µM treatment.
For in  vitro activation of IL-6 trans-signaling experiment, 
16HBE and 3T3 were treated with recombinant IL-6 10  ng/ml 
(R&D Systems, Minneapolis, MN, USA) for 48 h (46).
immunofluorescence
Collagen1-α immunofluorescence was performed in paraffin-
embedded sections of mouse lung. Before immunostaining, 
antigen retrieval was performed by heating slides in pH 6.0 citrate 
buffer at 100°C for 20 min in a microwave oven at 500 W using 
antigen retrieval solution (10  mM Tris and 1  mM EDTA, pH 
9.0). Non-specific antibody binding was blocked for 20 min by 
incubation with 0.05% w/v BSA in PBS. Slices were stained using 
the anti-collagen1-α antibody (Novus, Littleton, CO, USA, 1:100 
dilution) at 4°C overnight followed by staining with donkey-anti-
rabbit secondary antibody (Santa Cruz, CA, USA, 1:200 dilution) 
at 37°C for 2 h.
hematoxylin and eosin (h&e) staining and 
Masson’s Trichrome
Mouse lungs were harvested and placed in 4% paraformaldehyde 
for 48 h, then embedded in paraffin and cut into 5 μm-thick serial 
sections, finally stained with H&E or Masson’s trichrome.
analysis of mrna expression
Total RNA from whole-lung and cells were extracted using 
TRIZOL (Takara Bio, Kusatsu, Shiga, Japan) following 
the manufacturer’s instruction and then used to synthesize 
cDNA using the iScriptcDNA Synthesis Kit (Bio-Rad, Hercules, 
CA, USA). Relative gene expression was determined using 
real-time RT-PCR with the following primers: HomoIL-6: 
TTCGGTCCAGTTGCCTTCTC (forward), GAGGTGAGTG 
GCTGTCTGTG (reverse). MusIL-6: CCAATTTCCAATGCT 
CTCCT (forward), ACCACAGTGAGGAATGTCCA (reverse). 
HomoTGF-β: CCTGCCTGTCTGCACTATTC (forward), TGC 
CCAAGGTGCTCAATAAA (reverse). Mus TGF-β: CTGCTGA 
CCCCCACTGATAC (forward), GTGAGCGCTGAATCGAA 
AGC (reverse). Homo α-SMA: GATGGTGGGAATGGGACAAA 
(forward), GCCATGTTCTATCGGGTACTTC (reverse). Mus 
α-SMA: GTACCACCATGTACCCAGGC (forward), GCTGGA 
AGGTAGACAGCGAA (reverse). Homo COL1α: CAAGAGGA 
AGGCCAAGTCGAGG (forward), CGTTGTCGCAGACGCA 
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GAT (reverse). Mus COL1-α: CTGACGCATGGCCAAGAAGA 
(forward), TACCTCGGGTTTCCACGTCT (reverse). Homo 
GREM1: GCTAAAGAGAAGACGACGAGAG (forward), AGG 
GAGGTCATATCCCTTACA (reverse). Mus GREM1: CACTC 
GTCCACAGCGAAGAA (forward), TTGTGCTGAGCCTTGT 
CAGG (reverse). HomoFN1: TTGCTCCTGCACATGCTTTG 
(forward), CATGAAGCACTCAATTGGGCA (reverse). Homo 
STAT3: GCGGTAAGACCCAGATCCAG (forward), GGTCTT 
CAGGTATGGGGCAG (reverse). Homo GAPDH: AGAAGGCT 
GGGGCTCATTTG (forward), AGGGGCCATCCACAGTCTTC 
(reverse). Mus GAPDH: AGGTCATCCCAGAGCTGAACG (for-
ward), CACCCTGTTGCTGTAGCCGTAT (reverse). Mus 18s: 
CTCAACACGGGAAACCTCAC (forward), CGCTCCACCAA 
CTAAGAACG (reverse). Mus HDAC1: CTCACCGAATCCGC 
ATGACT (forward), ATTGGCTTTGTGAGGACGGT (reverse). 
Mus HDAC2: TATCCCGCTCTGTGCCCTAC (forward), GAG 
GCTTCATGGGATGACCC (reverse). Mus HDAC3: GGTGGC 
TACACTGTCCGAAA (forward), GGAGTGTGAAATCTGGG 
GCA (reverse). Mus HDAC4: GATGGACATCCACAGCAAGTA 
(forward), CTGTCTCAGCTTCTTCCTTCTC (reverse). Mus 
HDAC5: TTGACATCACAGCAGCTCCG (forward), ATGCCA 
TCTGCCGACTCGTT (reverse). Mus HDAC7: GGGCTCTTCC 
AGAACAGATTAG (forward), CCGAGGCCAAGTTAAGAAT 
AGT (reverse). Mus HDAC8: CCACCGAATCCAGCAAATCC 
(forward), CACAAACCGCTTGCATCAAC (reverse). Mus IL-1β: 
TCAGGCAGGCAGTATCACTC (forward), TCATCTCGGAGC 
CTGTAGTG (reverse). Mus IL-8 TTGGTGATGCTGGTCAT 
CTT (forward), TTTAGATGCAGCCCAGACAG (reverse). 
Mus COX2: AAGACTTGCCAGGCTGAACT (forward), CTT 
CTGCAGTCCAGGTTCAA (reverse). Mus MMP9: CCAGCCG 
ACTTTTGTGGTCT (forward), TGGCCTTTAGTGTCTGGC 
TG (reverse). Mus TNF-α: GACAGTGACCTGGACTGTGG 
(forward), TGAGACAGAGGCAACCTGAC (reverse). Mus 
VCAM1: GCCTCAACGGTACTTTGGAT (forward), GTGGG 
CTGTCTATCTGGGTT (reverse).
Western Blot of lung lysates
Whole-lung and cell protein were extracted using RIPA Lysis 
Buffer (Beyotime, Shanghai, China) according to the manufac-
turer’s instructions and then solubilized in 2× sample buffer. 
Protein concentration was determined with BCA Protein Assay 
Kit (Beyotime, Shanghai, China). Proteins were separated 
by SDS-polyacrylamide gel electrophoresis and transferred 
to polyvinylidene difluoride membrane (Bio-Rad, Hercules, 
CA, USA). The membranes were incubated with 5% non-fat 
dried milk for 60  min and then incubated with anti-α-SMA 
antibody (Sigma, St. Louis, MO, USA, 1:5,000 dilution) and 
anti-beta-actin antibody (Cell Signaling, Houston, TX, USA) at 
4°C overnight. Then, the membranes were incubated with an 
HRP-labeled secondary antibody (Santa Cruz Biotechnology, 
CA, USA, 1:5,000 dilution) at 37°C for 1 h and developed using 
the ECL detection Kit.
elisa analysis of IL-6 in Macrophage 
lysates and serum
The level of IL-6 was quantified in protein lysates purified from 
mice macrophages or serum using a mouse IL-6 ELISA Kit 
(ExCell Bio, Taicang, China). Lysate (50  µl) or serum samples 
(50 µl) were subjected to ELISA analysis according to the manu-
facturer’s protocol.
engineered crisPr–cas9 and Dna 
constructs
The use and design of engineered Cas9 complex and efficient 
sgRNA to induce IL-6 transcriptional activation followed the 
protocol of Dr. Zhang (37). The sgRNA primers were annealed 
and cloned into sgRNA (MS2)-plasmids via BbsI sites. All of the 
CRISPR constructs were purchased from Addgene (Cat: #61422, 
61423, 61424, 61362, and 61358). The IL-6 promoter-luciferase 
construct was generated by synthesizing the DNA fragment cor-
responding to IL-6 promoter region (IL-6 TSS −2,000 to 0) from 
GenScript and subcloning into pGL3-Basic vector.
chromatin immunoprecipitation (chiP)—
Quantitative Pcr (qPcr)
Chromatin immunoprecipitation was performed using the EZ 
ChIP™ Chromatin Immunoprecipitation Kit (Merck Millipore, 
Billerica, MA, USA) according to the manufacturer’s instructions. 
Macrophages were treated with vehicle (DMSO) or scriptaid 
(3  µg/ml) for 24  h and then fixed with 4% formaldehyde for 
10  min. Chromatin was then prepared by enzymatic shearing 
and optimized according to the manufacturer’s instructions. 
ChIP was performed using ChIP-IT express on sheared chroma-
tin from approximately 7.5 × 105 cells using a negative control 
IgG, an anti-H3K4me3antibody, and an anti-H3K9ac antibody. 
Real-time PCR was performed on DNA isolated from each of 
the ChIP reactions using specific primer pairs for the mouse IL-6 
promoter regions (F: CACTTCACAAGTCGGAGGCT and R: 
AATGAATGGACGCCCACACT). The ΔCt was calculated by 
the relative fold enrichment for each antibody used versus IgG 
negative control.
Promoter activity assays
Cells were transfected and the total amount of expression plas-
mid transfected per well was balanced with varying amounts of 
a control vector. Firefly luciferase reporter plasmids and control 
luciferase plasmid (Renilla luciferase) were cotransfected into 
the cells, and 24  h post-transfection, cells were treated with 
PQ, VPA and anacardic acid for another 24  h. Cells were 
eventually processed in lysis buffer (Promega, Madison, WI, 
USA), and promoter activity was measured by a dual luciferase 
system using firefly luciferase normalized to Renilla luciferase 
(Promega, Madison, WI, USA).
statistical analysis
Data are presented as mean ±  SEM. Statistical analysis was 
performed using Instat software (GraphPad Software Inc., 
San Diego, CA, USA). An unpaired Student’s t-test and an 
ANOVA analysis with a Bonferroni post  hoc test were used 
for single and multiple comparisons between two or more 
groups, respectively. The P < 0.05 was considered statistically 
significant.
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resUlTs
PQ-induced acute and chronic lung 
injury and increased IL-6 expression
We examined the effect of PQ-induced acute lung injury and 
chronic pulmonary fibrosis by performing H&E and Masson’s 
trichrome staining in the lung sections from PQ treated mice 
for 3 days and 1 month. As shown in Figure 1A, we found that 
inflammatory cells were infiltrated into lung structure in mice 
treated with PQ. With the prolongation of PQ treatment, the 
amount of collagen fibers was increased indicated by Masson’s 
trichrome staining (Figure  1B). As the exposure to PQ leads 
to significant inflammation and fibrosis in the lung, we next 
investigated the effect of PQ on the level of inflammation-related 
gene expression in vivo and in vitro. We found that PQ potently 
increases the mRNA and protein expression of IL-6 in a dose-
dependent manner in the lung and serum following PQ exposure 
(Figures 1C,D). While we did not observed a significant change 
in the level of IL-1β, IL-8, COX-2, MMP9, TNF-α, and VCAM1 
gene expression (Figures S1A–F in Supplementary Material). 
Since IL-6 is mainly produced in immune cells and fibroblasts, 
we then measured IL-6 mRNA and protein expression in mac-
rophages and found that PQ significantly increased the mRNA 
and protein expression of IL-6 in a dose-dependent and time-
dependent manner in macrophages (Figures 1E–G). However, 
the level of IL-6 remains unchanged in human lung fibroblast 
and epithelial cells 16HBE (Figures S2A,B in Supplementary 
Material).
involvement of eMT and associated IL-6 
in PQ-induced Pulmonary Fibrosis
To determine the functional role of IL-6 in PQ-induced pulmonary 
fibrosis, we next blocked IL-6 trans-signaling with recombinant 
soluble gp130Fc. PQ exposure significantly increased the expres-
sion level of TGF-β, α-SMA, GREM1, and FN1 in mouse lung, 
which were reduced in the presence of recombinant gp130Fc 
(Figures 2A–E). In addition, in vivo neutralization of IL-6 trans-
signaling by using recombinant gp130Fc attenuated pulmonary 
fibrosis phenotype (Figure 2F). IL-6 that is released from mac-
rophages into the extracellular space can also influence fibrosis 
and inflammation via paracrine actions on other cell types. We 
next treated mice fibroblasts with recombinant IL-6 protein and 
the fibrotic gene expression including α-SMA, GREM1, and FN1 
were unchanged (Figures S3A–C in Supplementary Material). 
To explore the role of IL-6 in the pathogenic mechanism of 
PQ-induced pulmonary fibrosis, we tested the levels of EMT-
related genes in epithelial cells. And we found EMT-related genes 
such as STAT3, TGF-β, α-SMA, GREM1, and FN1 were increased 
in association with the treatment of recombinant IL-6 in 16HBE 
(Figures 3A–E). To further understand the role of IL-6 in mediat-
ing macrophage and epithelial cell interaction, we treated 16HBE 
with PQ-treated macrophage lysates in the presence or absence of 
recombinant gp130Fc. These data showed that the expression of 
EMT-related genes were elevated in 16HBE following PQ-treated 
macrophage lysates but reduced in the presence of recombinant 
gp130Fc (Figures  3F–J). Together, our data demonstrated that 
PQ-induced IL-6 expression in macrophages plays a central role 
in pulmonary fibrosis through enhanced EMT transition.
IL-6 expression is associated with histone 
acetylation, and haT inhibition Mitigates 
PQ-induced Pulmonary Fibrosis
Given the previous data showing IL-6 play a vital role in pul-
monary fibrosis, we next explore its regulation mechanism. 
HDAC inhibitors have been shown to influence interstitial 
fibrosis (47–49). To determine the effect of histone acetylation on 
IL-6 expression, we measured IL-6 mRNA and protein expres-
sion in the lung, serum, and macrophages. We observed that 
PQ-induced upregulation of IL-6 mRNA and protein levels were 
further enhanced in the presence of the HDAC inhibitor VPA 
but reduced in the presence of the HAT inhibitor anacardic acid 
(Figures 4A–H). The ability to increase IL-6 expression was also 
observed with other HDAC inhibitors in macrophages, as we can 
see that IL-6 was significantly elevated in cells treated with the 
HDAC inhibitors suberoylanilide hydroxamic acid (SAHA) and 
scriptaid (Figure S4A in Supplementary Material). In addition, 
PQ-induced pulmonary acute inflammation was aggravated 
in the presence of VPA and mitigated in the presence of the 
anacardic acid (Figures 5A,B). For long-term (1 month) treat-
ment, Masson’s trichrome and COL1α immunofluorescence in 
lung sections indicated that anacardic acid reversed PQ-induced 
pulmonary fibrosis (Figures  5C,D). The data are consistent to 
the observation that the mRNA and protein level of EMT-related 
genes TGF-β, α-SMA, GREM1, and FN1 were decreased in the 
lung tissues from PQ-treated mice in the presence of anacardic 
acid (Figures 6A–E; Figure S4B in Supplementary Material). To 
determine the significance of HDACs in PQ-induced pulmonary 
fibrosis, we assessed the expression level of HDACs in the lung 
and macrophages. We found decreased the expression of HDAC3 
in PQ-treated lungs in a dose-dependent manner (Figure S5A in 
Supplementary Material). In macrophages treated with PQ, we 
also observed the loss of HDAC3 expression in a dose-dependent 
and time-dependent manner (Figures S5B,C in Supplementary 
Material). While the mRNA level of HDACs 1, 2, 5, and 7 were 
significantly increased in the presence of PQ, and the expres-
sion of HDACs 4 and 8 remain unchanged (Figures S5D–I in 
Supplementary Material).
epigenetic regulation of IL-6 by histone 
acetylation
We next determined whether inhibition of HDACs or HATs 
affects IL-6 promoter activity. We used IL-6 promoter- 
luciferase reporter plasmids containing the proximal 5′ reporter 
region upstream of the transcription start site. The relative IL-6 
promoter was enhanced in the presence of HDAC inhibitor VPA, 
which remains unchanged in the presence of HAT inhibitor 
anacardic acid and PQ (Figure 7A). Given that the inability of 
PQ to modify IL-6 promotor activity and the differences between 
promoter assay and native gene expression, we next assessed the 
epigenetic regulatory mechanisms of IL-6 transcription.
As a tool to interrogate the epigenetic regulations of IL-6 
expression, we employed a CRISPR-ON strategy which based 
FigUre 1 | Paraquat (PQ)-induced acute pulmonary inflammation, pulmonary fibrosis, and increased IL-6 expression. Wild-type C57BL/6 male mice 
were treated with vehicle (saline) or 10 mg/kg of PQ for 3 days or 1 month. (a) Lung sections from 3-day mice were stained with hematoxylin and eosin staining for 
visualization of inflammatory cell infiltration. (B) Lung sections from day 30 mice were stained with Masson’s trichrome for visualization of collagen deposition (green). 
(c) IL-6 was measured in whole-lung RNA of 3-day mice. (D) ELISA measurement of IL-6 in the serum of day 3 mice. (e) Macrophages were treated with increasing 
concentrations of PQ for 24 h, and IL-6 mRNA expression was determined by real-time PCR. (F) ELISA measurement of IL-6 in lysates of macrophages.  
(g) Macrophages were treated with PQ (80 µM) for 0, 4, 8, 12, and 24 h, and IL-6 mRNA expression was determined by real-time PCR. Sections are representative 
of n ≥ 5 mice from each group. Macrophages were plated in six-well plates at a density of 1.5–2 × 106 cells/well, and the data are representative of n > 5 from each 
group. Data are expressed as means ± SEM, *P < 0.05 versus vehicle.
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on the inactive Cas9 enzyme. As shown in Figures  7B,C, 
CRISPR-ON targeted to the IL-6 promoter regions increased 
the expression of IL-6. The ability of CRISPR-ON to drive IL-6 
gene transcription was increased in the presence of VPA while 
attenuated in the presence of anacardic acid. P300 is a highly 
conserved acetyltransferase involved in a wide range of cellular 
processes. The fusion of p300 to dCas9 enables p300 to specifi-
cally target this enzyme to the endogenous promoters of IL-6. As 
shown in Figure 7D, the dCas9p300 Core fusion increased IL-6 
expression by transient cotransfection with sgRNA targeting 
the endogenous promoters of IL-6 in human HEK293T cells. 
A single inactivating amino acid substitution within the HAT 
core domain of dCas9p300 Core [dCas9p300 Core (D1399Y)] 
abolished the transactivation capacity of the fusion protein, 
demonstrating that p300 HAT domain is sufficient to activate 
IL-6 transcription.
FigUre 2 | continued
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FigUre 3 | Paraquat (PQ)-induced pulmonary fibrosis through epithelial-to-mesenchymal transition. (a–e) 16HBE cells were treated with vehicle or 
recombinant IL-6 10 ng/ml for 48 h. STAT-3, TGF-β, α-smooth muscle actin (α-SMA), GREM1, and FN1 mRNA expression were determined by real-time PCR. Bar 
graphs show the normalized levels of STAT-3, TGF-β, α-SMA, GREM1, and FN1 by GAPDH. (F–J) 16HBE were incubated with or without 50% macrophage lysates 
that were treated with or without PQ or recombinant gp130Fc. STAT-3, α-SMA, TGF-β, GREM1, and FN1 mRNA expression were determined by real-time PCR. 
16HBE cells were plated in six-well plates at a density of 1.5–2 × 106 cells/well, and the data are representative of n > 5 from each group. *P < 0.05 versus vehicle 
and #P < 0.05 versus 50% macrophage lysates (n = 4–6).
FigUre 2 | continued  
gP130Fc downregulated the expression of fibrotic markers and ameliorated paraquat (PQ)-induced pulmonary fibrosis. Wild-type mice were injected 
with saline or PQ 10 mg/kg, respectively, for 33 days. Mice were treated with vehicle (200 µl sterile PBS) or gp130Fc (2 µg/mouse reconstituted in 200 µl sterile 
PBS) 1 h before and 18 days after PQ injection. (a–D) The mRNA expression of TGF-β, α-smooth muscle actin (α-SMA), GREM1, and FN1 were measured in 
whole-lung RNA. (e) Western blot analysis of α-SMA expression in whole-lung lysates. (F) Masson’s trichrome for collagen deposition (green). Representative 
images of n = 4–6 mice from each group are shown. Data are expressed as means ± SEM, *P < 0.05 versus vehicle and #P < 0.05 versus PQ alone.
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FigUre 4 | histone acetylation regulates IL-6 expression. (a,B) Wild-type C57BL/6 male mice were treated with vehicle (saline) or 10 mg/kg of  
paraquat (PQ) for 3 days, and mice received VPA (3.5 mg/kg) or anacardic acid (5 mg/kg) starting 24 and 1 h before PQ injection. IL-6 mRNA expression was 
determined by real-time PCR. (c,D) Macrophages were treated with vehicle or PQ (80 µM) for 24 h, and cells received VPA (1 mM) or anacardic acid (25 µM) 
starting 1 h before PQ treatment. IL-6 mRNA expression was determined by real-time PCR. (e–h) ELISA measurement of IL-6 in serum of day 3 mice and in 
lysates of macrophages in the above mentioned experimental groups. Data are expressed as means ± SEM, *P < 0.05 versus vehicle and #P < 0.05 versus PQ 
(n = 4–6).
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FigUre 5 | continued
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FigUre 5 | changes in pulmonary acute inflammation, pulmonary fibrosis following paraquat (PQ) exposure in mice treated with histone 
deacetylase or histone acetyltransferase inhibitors. Wild-type C57BL/6 male mice were treated with vehicle (saline) or 10 mg/kg of PQ for 3 days, and mice 
received VPA (3.5 mg/kg) or anacardic acid (5 mg/kg) starting 24 and 1 h before PQ injection. (a,B) Lung sections from day 3 mice were stained with hematoxylin 
and eosin staining for visualization of inflammatory cell infiltration. Wild-type C57BL/6 male mice were treated with vehicle (saline) or 10 mg/kg of PQ for1 month, 
and mice received anacardic acid (5 mg/kg) starting 1 h before PQ injection, 24 h and 15 days after PQ injection. (c) Lung sections from day 30 mice were stained 
with Masson’s trichrome for visualization of collagen deposition (green). (D) COL1-α immunofluorescence (red) in lung sections. Sections are representative of 
n = 4–6 mice from each group.
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Chromatin immunoprecipitation–qPCR experiments were 
employed to ascertain epigenetic changes at the IL-6 promoter 
regions in macrophages. As shown in Figures  7E,F, marks of 
open chromatin structures including trimethylation of lysine 4 of 
histone H3 (H3K4me3) and acetylation of lysine 9 of histone H3 
(H3K9ac) binding at the IL-6 promoter region were significantly 
increased in the presence of HDAC inhibitor, scriptaid.
DiscUssiOn
The purpose of this study was to explore the effect of IL-6 on 
PQ-induced pulmonary fibrosis and further to interpret its under-
lying mechanisms. We found that PQ could dose-dependently 
and time-dependently increase IL-6 mRNA expression from 
lung tissues and macrophages concomitant with the upregula-
tion of protein expression. In addition to IL-6 expression, PQ 
also harbored the ability to induce pulmonary acute inflamma-
tion and pulmonary fibrosis. Pulmonary fibrosis and fibrotic 
genes can be alleviated by blocked IL-6 trans-signaling with 
recombinant soluble gp130Fc. IL-6 release from macrophages in 
response to PQ mainly plays a central role in pulmonary fibrosis 
through enhanced EMT transition in pulmonary epithelial 
cells. Mechanistically, histone acetylation could enhance the 
transcription of IL-6, which is involved in the progression of 
PQ-induced pulmonary fibrosis. Histone acetylation didn’t alter 
the activity of transiently expressed IL-6 promoter-luciferase 
constructs. ChIP–qPCR experiments revealed increased levels 
of H3K4me3 and H3K9ac at IL-6 promoter sites in the presence 
of HDAC inhibitor, indicating that HDAC inhibitor could alter 
chromatin accessibility. As followed, the ability of CRISPR-ON 
to stimulate transcription of the endogenous IL-6 genes was 
reduced in the presence of HAT inhibitor and enhanced in the 
presence of HDAC inhibitor. Targeting p300 HAT core domain 
to the endogenous promoters of IL-6 significantly increased IL-6 
transcription. Together, our study uncovered the epigenetic regu-
latory mechanism of IL-6 in macrophages that played a critical 
role in PQ-induced pulmonary fibrosis.
Interleukin 6, described as a cytokine regulating immune-
neural-endocrine, participates in cell growth, differentiation, and 
function adjustment and plays an important role in the immune 
and inflammatory response. Although various cytokines are 
involved in the localized tissue injury or systemic damage, IL-6 is 
a kind of important inflammatory mediator response to localized 
tissue injury. IL-6-deficient mice cannot mount a normal inflam-
matory response to localized tissue damage induced by turpentine 
treatment and the expression of induced acute phase proteins goes 
an apparent decline (50). IL-6 binds IL-6R and associates with two 
molecules of gp130 to initiate the intracellular signaling cascade 
to exert its biological functions (51). A growing body of studies 
indicates that IL-6 takes part in occurrence and development of 
fibrosis diseases (19, 20, 52, 53). Fibrosis is characterized by fibro-
blast aggregation, ECM deposition accompanied by disruption of 
the normal tissue structure and function caused by inflammation 
and injury (4, 54). Some cytokines involved in the formation of 
fibrosis diseases were confirmed by the experiments in vitro and 
in vivo. The role of cytokines in fibrosis formation has become 
a hot spot of research and IL-6 has ability to promote fibrosis 
formation alone or together with TNF-α in bleomycin-induced 
FigUre 6 | influence of histone acetyltransferase inhibition on gene expression of fibrotic markers. Wild-type C57BL/6 male mice were treated with 
vehicle (saline) or 10 mg/kg of paraquat (PQ) for 1 month, and mice received anacardic acid (5 mg/kg) starting 1 h before PQ injection, 24 h and 15 days after PQ 
injection. (a–D) TGF-β, α-smooth muscle actin (α-SMA), GREM1, and FN1 expression were determined by real-time PCR. (e) Western blot analysis of α-SMA 
expression in whole-lung lysates. Data are expressed as means ± SEM, *P < 0.05 versus vehicle and #P < 0.05 versus PQ (n = 4–6).
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pulmonary fibrosis. In addition, previous study indicates a possi-
ble association between sensitivity to bleomycin-induced fibrosis 
and inducibility of IL-6 mRNA upon drug treatment (55).
Interleukin-6 increased significantly in bleomycin-induced 
pulmonary fibrosis and other fibrosis diseases such as liver fibro-
sis, cystic fibrosis, and systemic scleroderma (56, 57). Therefore, 
IL-6 is described not only as a classic proinflammatory cytokine 
but also as a profibrotic factor, even though the exact underlying 
mechanism remains a mystery (18, 23, 58). In our study, we dem-
onstrated that IL-6 overexpression in PQ-induced pulmonary 
fibrosis and blockade of GP130Fc reduced IL-6-induced fibrosis-
related genes induction. Collectively, the above data suggested 
that IL-6 did play an important role in pulmonary fibrosis, but 
the exact mechanism is elusive.
Despite a large amount of research investigating this area, it is 
rather surprising that it is still unknown at the molecular level how 
FigUre 7 | continued
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FigUre 7 | continued  
Modulation of endogenous IL-6 expression using crisPr-On, and the effects of histone deacetylase (hDac) or histone acetyltransferase inhibition 
and epigenetic regulation of IL-6 transcription by hDac inhibition. (a) HEK 293 T cells cotransfected with Firefly luciferase (LUC) reporter plasmids consisting 
of human IL-6 promoter and Renilla luciferase as a transfection control were treated with vehicle (DMSO), paraquat (20, 40, 60, and 80 μM), anacardic acid (25 µM), 
or VPA (1mM) for 24 h, and luciferase activity determined using a Polarstar Omega (BMG Labtech, Durham, NC, USA) luminometer. (B) Schematic of the 
CRISPR-ON strategy to activate IL-6 gene expression. (c) Guide RNA (gRNA) sequences and binding regions on the IL-6 promoters. HEK-293 cells were 
transfected with either a control gRNA or gRNA targeting the proximal IL-6 promoter regions in the presence or absence of VPA (1 mM) or anacardic acid (25 µM) 
for 24 h. (D) HEK-293 cells were co-transfected with IL-6 gRNA and dCas9-p300 or dCas9-p300 (D1399Y) plasmids. IL-6 mRNA levels were determined by 
real-time PCR relative to GAPDH. (e,F) Macrophages treated with vehicle (DMSO) or scriptaid (3 µg/ml) were fixed with 1% formaldehyde for 10 min and chromatin 
prepared by enzymatic shearing for 10 min. ChIP was performed on isolated sheared chromatin using a negative control IgG and ChIP grade antibodies to H3K4 
trimethylation (H3K4me3) or H3K9 acetylation (H3K9ac). Real-time PCR was performed on DNA purified from each of the ChIP reactions using primers specific for 
the IL-6 promoter regions located upstream of IL-6 transcriptional start site. HEK 293 T cells were plated in 12-well plates at a density of 0.5–1 × 106 cells/well, and 
the data are representative of n > 5 from each group. Macrophages were plated in 100 mm dish at a density of 1–1.5 × 107 cells/dish, and the data are 
representative of n > 5 from each group. Data are expressed as means ± SEM, *P < 0.05 (n = 4–6).
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IL-6 leads to fibrosis and which downstream signaling pathway 
contributes to this ECM deposition. Transdifferentiation of cardiac 
fibroblasts to the pathogenic myofibroblasts mediated by IL-6 has 
been reported (54). In a rat model of cardiac hypertrophy by artery 
ligation, collagen synthesis and hypertrophy occur but inhibition 
of IL-6 resulted in blockade of fibrosis and hypertrophy suggesting 
that IL-6-mediated collagen synthesis is driving the fibrosis and 
hypertrophy through a direct mechanism. However, in our study, 
we demonstrated that IL-6 leads to fibrosis aggravation through 
an indirect mechanism that is mediated by EMT transition. Since 
IL-6 plays a vital role in PQ-induced fibrosis, the mechanisms 
underlying the regulation of IL-6 remain unknown. To this end, 
we next studied the epigenetic regulatory mechanism of IL-6.
Epigenetic modifications of chromatin are classic tools to regu-
late genes expression (24). Activity of HDAC family enzymes that 
catalyze the removal of diacetyl or acetyl groups from proteins 
was linked with development and progression of fibrosis (31, 
59). While the functions of HAT are opposite. HDAC inhibitors, 
especially class I and II inhibitors, theoretically should increase 
histone acetylation and gene transcription. Our study shows that 
HDAC inhibitors promote the expression of IL-6 mRNA and 
protein, thus PQ-induced pulmonary fibrosis was aggravated. 
In contrast, previous studies reported that the HDAC inhibitor 
mocetinostat decreased IL-6 expression in congestive heart failure 
myocardium and cardiac fibroblasts (49, 60, 61). Increased HDAC 
activity has been found to be associated with fibrotic disorders, 
and the application of HDAC inhibitors could provide a potential 
benefit in the treatment of fibrotic disorders (62). In human lung 
fibroblasts, HDAC inhibitor TSA reduced TGF-β-induced α-SMA 
and collagen 1-α expression (63). While other investigators have 
found the reduced HDAC activity and increased HAT activity 
in inflammatory lung disease, especially HDAC2 expression and 
activity was reduced in COPD (27, 64). The treatment of HDAC 
inhibitor TSA caused right ventricle dysfunction and fibrosis in a 
rat model of pulmonary artery binding (65). Increased oxidative 
stress could suppress HDAC activity and expression, which is 
important to reduce inflammatory gene expression in the lung and 
macrophages, thus HDAC activator might have important clinical 
implications in severe asthma and cystic fibrosis (25). The reasons 
underlying this discrepancy are not known but may be due to a 
model-dependent effect or a cell type-dependent effect or HDAC 
inhibitor type-dependent effect. We found that multiple HDAC 
inhibitors effectively increase IL-6 expression in macrophages 
in vitro and in PQ-treated lung tissues in vivo. In addition, the 
ability of HDAC inhibitors to modify gene expression is complex, 
previous studies demonstrated that approximately 30% of the 
transcriptome are regulated by HDACs with equal proportion of 
the upregulation and downregulation in gene expression, and the 
pattern and direction of changes in gene expression are different 
and depended on cell types (33, 34). This is partially due to the fact 
that HDAC inhibitors can significantly increase the deacetylation 
of histones at multiple genomic DNA regions (33). VPA inhibits 
HDAC classes I (HDAC1, 2, 3, and 8) and II, while scriptaid and 
SAHA specifically inhibit HDAC class I. We found low expression 
of HDAC3, 4, and 8 and overexpression of HDAC1, 2, 5, and 7 
in PQ-treated macrophages and lungs. Whether the increased 
IL-6 expression is connected with these decreased HDACs is not 
fully understood. On the contrary, HAT inhibitor anacardic acid 
inhibited the expression of IL-6 and alleviated fibrosis.
To interrogate the relationship between the HDAC and 
HAT with IL-6 regulation, here we have employed CRISPR-ON 
which on the basis of CRISPR/Cas9 gene regulation system. The 
efficiency of CRISPR-ON could be influenced by chromatin 
remodeling with the help of RNA guides and dCAS9. We found 
that the HAT inhibitor anacardic acid reduced the ability of 
CRISPR-ON to increase IL-6 mRNA expression and HDAC 
inhibitor VPA increased the ability of CRISPR-ON to increase 
IL-6 mRNA expression. These results indicate that the chromatin 
remodeling controlled by histone modifications around the 
promoter sequences of IL-6 gene is important in regulating its 
transcriptional activity. As a potent easily programmable tool 
to regulate acetylation at targeted endogenous loci, dCas9p300 
Core fusion protein leading to manipulate targeted genes with the 
help of intrinsic p300 Core acetyltransferase activity. In our study, 
dCas9p300 Core fusion protein increased IL-6 mRNA expression 
and the dCas9p300 Core (D1399Y) acetyltransferase-null mutant 
had lower ability to increase the IL-6 mRNA expression. Thus, 
transcriptional coactivator p300/CBP, with HAT activity, plays 
a role in influencing the IL-6 expression (66). These results are 
also supported by ChIP analysis, which revealed that HDAC 
inhibitors scriptaid increased the presence of histones bearing 
activation marks (H3K4me3 and H3K9ac) at the IL-6 promoter 
regions, suggesting that chromatin accessibility in the region of 
the IL-6 promoter is increased by HDAC inhibition.
In summary, our study reveals the role of IL-6 in PQ-induced 
pulmonary fibrosis and a new epigenetic mechanism that controls 
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FigUre s1 | expression of inflammation-related genes in lung from 
paraquat (PQ)-treated mice. Wild-type C57BL/6 male mice were treated with 
vehicle (saline), 10 or 50 mg/kg of PQ for 3 days. (a) IL-1β, (B) IL-8, (c) COX-2, 
(D) MMP9, (e) TNF-α, and (F) VCAM1 mRNA expression in the lung were 
measured by real-time PCR. Data are expressed as mean ± SEM, *P < 0.05 
versus vehicle (n = 3–6).
FigUre s2 | expression of interleukin 6 (IL-6) mrna in paraquat 
(PQ)-treated 16hBe and hlF. (a) 16HBE and (B) HLF were treated with 
increasing concentrations of PQ for 24 h, and IL-6 mRNA expression was 
determined by real-time PCR. 16HBE and HLF cells were plated in six-well  
plates at a density of 1.5–2 × 106 cells/well, and the data are representative of 
n > 5 from each group. Data are expressed as mean ± SEM (n = 3–6).
FigUre s3 | influence of recombinant interleukin 6 (IL-6) had no impact 
on the expression of fibrotic genes in fibroblasts. Fibroblasts 3T3 were 
treated with vehicle or recombinant IL-6 10 ng/ml for 48 h. And (a) α-smooth 
muscle actin (α-SMA), (B) GREM1, and (c) FN1 expression were determined by 
real-time PCR. Fibroblasts 3T3 were plated in six-well plates at a density of  
1.5–2 × 106 cells/well, and the data are representative of n > 5 from each group. 
Data are expressed as mean ± SEM (n = 3–6).
FigUre s4 | regulation of interleukin 6 (IL-6) expression by histone 
deacetylase inhibition and the densitometry analysis of α-sMa in PQ and 
anacardic acid treated mice lung. (a) Macrophages were treated with vehicle 
or scriptaid 3 mg/ml, suberoylanilide hydroxamic acid 10 mM for 24 h. IL-6 
mRNA was determined by real-time PCR. Data are expressed as mean ± SEM, 
*P < 0.001 versus vehicle (n = 3–6). (B) Densitometry analysis of α-smooth 
muscle actin (α-SMA) versus β-actin in lungs from control or paraquat (PQ) or 
anacardic acid (5 mg/kg) treated mice lung. Results are representative of at least 
three to five separate experiments. Data are expressed as means ± SEM, 
*P < 0.05 versus control, and #P < 0.05 versus PQ.
FigUre s5 | expression of histone deacetylase (hDac) mrna in 
paraquat (PQ)-treated lung and macrophages. (a) HDAC3 mRNA 
expression was measured in lung from control and day 3 PQ-treated mice. (B–i) 
The relative expression of HDAC1, HDAC2, HDAC4, HDAC5, HDAC7, and 
HDAC8 were determined by real-time PCR relative to GAPDH in PQ-treated 
macrophages. Data are expressed as mean ± SEM, *P < 0.05 versus vehicle 
(n = 4–6).
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